Cresset Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
VCM
VPM
Cresset Asset Management's BMY Position: Q1 2026 in Review
Cresset Asset Management increased its Bristol-Myers Squibb (BMY) stake by 16% in Q1 2026, buying an estimated $3.4M and bringing the position to 412,464 shares worth $25M. The position accounts for 0.11% of the portfolio, ranked #127.
Cresset Asset Management first reported a position in BMY in Q4 2018 and has held it in 30 quarters since. The position peaked at $30M in Q2 2022. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Cresset Asset Management held 412,464 shares of Bristol-Myers Squibb worth $25M as of Q1 2026.
- Cresset Asset Management bought 58,269 Bristol-Myers Squibb shares in Q1 2026, an estimated $3.4M.
- Bristol-Myers Squibb made up 0.11% of Cresset Asset Management's portfolio in Q1 2026, its #127 holding.
- Cresset Asset Management first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 30 quarters since.
- Cresset Asset Management's Bristol-Myers Squibb position peaked at $30M in Q2 2022.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.